Tuberculosis and lung diseases | 2021

COVID-19 and chronic obstructive pulmonary disease: what is known about the unknown

 
 
 
 
 

Abstract


The article reviews 60 publications and addresses key aspects of concurrent COVID-19 and chronic obstructive pulmonary disease (COPD) It presents data stating that COPD patients have higher expression of the receptor of angiotensin-converting enzyme 2 in the lungs and this may contribute to a greater susceptibility to COVID-19 In COPD, signs of endothelial cell dysfunction and tendency to thrombus formation have been identified which can present the risk of unfavorable outcomes of COVID-19 Cohort study data do not confirm that COPD patients are more susceptible to SARS-CoV-2 infection, but their clinical outcomes of COVID-19 appear to be worse including the need for mechanical ventilation and lethality There is no clinical evidence about the role of inhaled glucocorticosteroids used to manage COPD in the development and course of COVID-19 © 2021 New Terra Publishing House All rights reserved

Volume 99
Pages 6-15
DOI 10.21292/2075-1230-2021-99-2-6-15
Language English
Journal Tuberculosis and lung diseases

Full Text